Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Subject-blind, Investigator-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of UCB4940 in Subjects With Psoriatic Arthritis

Trial Profile

A Subject-blind, Investigator-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of UCB4940 in Subjects With Psoriatic Arthritis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors UCB
  • Most Recent Events

    • 23 Dec 2017 Primary endpoint (Pre-specified efficacy (PoC) endpoint:American College of Rheumatology Index of Improvement (ACRn) at Week 8 (pooled top three doses vs placebo at week 80))has been met, according to results published in the Annals of the Rheumatic Diseases.
    • 23 Dec 2017 Results of the preclinical experiments and a proof of concept (PoC) study assessing the effect of novel dual-cytokine blockade (IL-17A and IL-17F) by Bimekizumab versus placebo, published in the Annals of the Rheumatic Diseases.
    • 10 Jun 2016 According to an UCB media release, positive results (n=52) were presented at the Annual European Congress of Rheumatology (EULAR) 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top